Amiodarone keratopathy.
Thirty-eight patients received an average of 325 mg of amiodarone per day (range, 100 to 600 mg/day) for an average period of 16 months (range, nine to 30 months). Visible corneal microdeposits developed in all patients. Ninety-five percent of our patients had grade I or grade II keratopathy with no effect on vision. Five percent (5%) had grade III keratopathy with loss of one line of visual acuity and experienced subjective blurring and colored halos. Although there was a relationship of the total cumulative dose of the drug to the density of the corneal microdeposits, there was great variability from patient to patient, which limited the usefulness of this relationship.
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001572:Benzofurans / Q000009:adverse effects*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000145:classification; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D001572:Benzofurans; D000638:Amiodarone